22/11/2022 - 13:10 - 14:40
CC5.12 - COVID-19: ESTUDOS POPULACIONAIS SOBRE PERFIL DE PACIENTES E COBERTURA VACINAL |
39917 - SARS-COV-2 HUMORAL IMMUNITY AND POST-ACUTE COVID SYNDROME AMONG THE EPIPORTO COHORT
JOANA PINTO DA COSTA - EPIUNIT - INSTITUTO DE SAÚDE PÚBLICA, UNIVERSIDADE DO PORTO, PORTO, PORTUGAL, PAULA MEIRELES - EPIUNIT - INSTITUTO DE SAÚDE PÚBLICA, UNIVERSIDADE DO PORTO, PORTO, PORTUGAL, ANGÉLICA RAMOS - SERVIÇO DE PATOLOGIA CLÍNICA, CENTRO HOSPITALAR UNIVERSITÁRIO DE SÃO JOÃO, PORTO, PORTUGAL, JOÃO TIAGO GUIMARÃES - SERVIÇO DE PATOLOGIA CLÍNICA, CENTRO HOSPITALAR UNIVERSITÁRIO DE SÃO JOÃO, PORTO, PORTUGAL, HENRIQUE BARROS - EPIUNIT - INSTITUTO DE SAÚDE PÚBLICA, UNIVERSIDADE DO PORTO, PORTO, PORTUGAL
Apresentação/Introdução
More than two years after the first cases of SARS-CoV-2 infection, there is evidence of memory B cell and T cell immune responses in infected as well as in vaccinated persons. There’s also evidence of the persistence/incidence of symptoms after the acute phase of the infection, a condition termed post-acute COVID-19 syndrome (PACS) associated with additional societal and health care costs.
Objetivos
We aimed to evaluate the prevalence of SARS-CoV-2 humoral immunity markers and to estimate the incidence of PACS among the population-based cohort of Porto (EPIPorto) and their cohabitants.
Metodologia
This study is nested in the EPIPorto cohort, a representative sample of 2485 community dwellers of Porto assembled between 1999-2003. EPIPorto participants and their cohabitants are being invited to a follow-up evaluation. Procedures include a questionnaire and blood collection to perform a multiplex assay for SARS-CoV-2 anti-spike (anti-S) and anti-nucleocapsid (anti-N) IgG antibodies. Serological evidence of infection was defined as having anti-N antibodies or anti-S in the absence of the COVID-19 vaccine. PACS was defined as reporting symptoms three months after diagnosis perceived to be associated with the SARS-CoV-2 infection. Up until March 17, 2022, 567 participants were evaluated.
Resultados
Preliminary data show that Ab were detectable in 557 (98.2%) participants; 554 (99.5%) had anti-S, 117 (21.0%) had anti-N, and 10 (1.8%) had no detectable Ab. Therefore, we estimated that 119 (21.0%) participants had evidence of infection, and 438 (77.2%) had humoral response most likely induced only by vaccination. Of those without previous diagnosis, 36 (8.2%) had serological evidence of previous infection. Of those vaccinated with at least one dose (n=549), 544 (99.1%) had anti-S Ab. We estimated that 14.1% of those previously diagnosed (n=128) suffered from PACS.
Conclusões/Considerações
Most of the evaluated participants had detectable humoral response specific for SARS-CoV-2 – either due to vaccination or previous infection. Those without detectable Ab after vaccination/diagnosis had either been vaccinated/diagnosed less than a month ago or 6 or more months ago. The prevalence of PACS is, as expected, lower than those found in cohorts of COVID-19 patients admitted to hospital but close to those found in the general population.
|
